We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Advanced Technology To Accelerate Development of Next-Generation Biotherapeutics

Advanced Technology To Accelerate Development of Next-Generation Biotherapeutics content piece image

Biopharmaceutical companies are transitioning from the development of standard monoclonal antibody therapies to more intricate antibody structures and new genetic medicines. Not only are these molecules more complex, but scientists are also under tremendous pressure to understand molecular liabilities sooner and close the developability gap in a much shorter time frame. As such, analytical evaluation of these sophisticated samples is getting more complex, more numerous and results are required in less time. As a result, investigators are in dire need of technologies that are fast and robust enough to keep up with the development pace of next-generation biotherapeutics.

Watch this webinar to learn about the latest technologies purpose-built to meet the challenges of the biopharmaceutical industry such as:

  • A multi-capillary electrophoresis system that enables researchers to run multiple samples significantly faster than traditional methods
  • A novel LC-MS/MS QTOF instrument for complex protein therapeutic analysis
A picture of Sahana Mollah
Sahana Mollah
Senior Manager, CE/Biopharma Applications
A picture of Andrew Mahan
Andrew Mahan
Principal Scientist/MS Group Leader, Cell & Developability Sciences Janssen Pharmaceutical Companies of Johnson & Johnson
A picture of Zoe Zhang, PhD
Zoe Zhang, PhD
Manager, Biopharma Applications, SCIEX